新型冠状病毒肺炎与肥胖症：流行病学、发病机制及治疗
COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment.
作者信息
Zhu Xinyu, Yang Liu, Huang Kai
机构信息
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Clinical Center for Human Genomic Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
出版信息
Diabetes Metab Syndr Obes. 2020 Dec 14;13:4953-4959. doi: 10.2147/DMSO.S285197. eCollection 2020.
Abstract
The growing prevalence of overweight and obesity has been a worldwide public health issue. During the COVID-19 pandemic, obesity is associated with a higher risk of severity and a worse clinical outcome of SARS-COV-2 infection. This may be because of the chronic low-grade inflammation, impaired immune response and metabolic disorders in obese patients. In this narrative review, we have summarized the association between obesity and COVID-19 and discussed the potential pathogenesis and treatment in these patients. This work may provide practical suggestions on the clinical management of obese COVID-19 patients.
摘要
超重和肥胖患病率的不断上升已成为一个全球性的公共卫生问题。在新冠疫情期间，肥胖与感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）后病情加重及临床预后较差的风险相关。这可能是由于肥胖患者存在慢性低度炎症、免疫反应受损及代谢紊乱。在这篇叙述性综述中，我们总结了肥胖与新冠病毒病（COVID-19）之间的关联，并讨论了这些患者潜在的发病机制及治疗方法。这项工作可为肥胖的COVID-19患者的临床管理提供实用建议。
相似文献
1
COVID-19 and Obesity: Epidemiology, Pathogenesis and Treatment.新型冠状病毒肺炎与肥胖症：流行病学、发病机制及治疗
Diabetes Metab Syndr Obes. 2020 Dec 14;13:4953-4959. doi: 10.2147/DMSO.S285197. eCollection 2020.
2
Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations.新冠疫情期间的肥胖大流行：叙述性综述与未来考量
Clin Nutr. 2021 Apr;40(4):1637-1643. doi: 10.1016/j.clnu.2021.02.038. Epub 2021 Mar 2.
3
COVID-19 severity in obese patients: Potential mechanisms and molecular targets for clinical intervention.肥胖患者 COVID-19 严重程度：临床干预的潜在机制和分子靶点。
Obes Res Clin Pract. 2021 Mar-Apr;15(2):163-171. doi: 10.1016/j.orcp.2021.01.004. Epub 2021 Jan 19.
4
SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients.超重和肥胖的 COVID-19 患者的 SARS-CoV-2 特异性免疫应答。
Front Immunol. 2023 Nov 2;14:1287388. doi: 10.3389/fimmu.2023.1287388. eCollection 2023.
5
Dysregulated Inflammation During Obesity: Driving Disease Severity in Influenza Virus and SARS-CoV-2 Infections.肥胖相关的炎症失调：在流感病毒和 SARS-CoV-2 感染中导致疾病严重程度加重。
Front Immunol. 2021 Oct 28;12:770066. doi: 10.3389/fimmu.2021.770066. eCollection 2021.
6
Obesity and Risk of COVID-19 Infection and Severity: Available Evidence and Mechanisms.肥胖与 COVID-19 感染和严重程度的关系：现有证据和机制。
Adv Exp Med Biol. 2021;1321:97-107. doi: 10.1007/978-3-030-59261-5_8.
7
Obesity and COVID-19 Pandemics: Epidemiology, Mechanisms, and Management.肥胖与新冠疫情：流行病学、机制与管理
Diabetes Metab Syndr Obes. 2023 Dec 20;16:4147-4156. doi: 10.2147/DMSO.S441762. eCollection 2023.
8
N6-Acetyl-L-Lysine and p-Cresol as Key Metabolites in the Pathogenesis of COVID-19 in Obese Patients.N6-乙酰-L-赖氨酸和对甲酚作为肥胖患者 COVID-19 发病机制中的关键代谢物。
Front Immunol. 2022 May 19;13:827603. doi: 10.3389/fimmu.2022.827603. eCollection 2022.
9
From Influenza Virus to Novel Corona Virus (SARS-CoV-2)-The Contribution of Obesity.从流感病毒到新型冠状病毒（SARS-CoV-2）——肥胖的贡献。
Front Endocrinol (Lausanne). 2020 Oct 6;11:556962. doi: 10.3389/fendo.2020.556962. eCollection 2020.
10
Patients with Severe Obesity during the COVID-19 Pandemic: How to Maintain an Adequate Multidisciplinary Nutritional Rehabilitation Program?新冠疫情期间的重度肥胖患者：如何维持充分的多学科营养康复计划？
Obes Facts. 2021;14(2):205-213. doi: 10.1159/000513283. Epub 2021 Mar 19.
引用本文的文献
1
Prevalence of comorbidities and their association with disease severity and mortality in COVID-19 patients: A systematic review and meta-analysis.COVID-19患者合并症的患病率及其与疾病严重程度和死亡率的关联：一项系统综述和荟萃分析。
J Multimorb Comorb. 2025 Aug 28;15:26335565251371256. doi: 10.1177/26335565251371256. eCollection 2025 Jan-Dec.
2
Obesity and COVID-19: Pathophysiological Insights and Pulmonary Complications in a Retrospective Cohort Study.肥胖与2019冠状病毒病：一项回顾性队列研究中的病理生理学见解与肺部并发症
Biomedicines. 2025 Aug 18;13(8):2009. doi: 10.3390/biomedicines13082009.
3
Regulation of pyroptosis in diabetic nephropathy by long non-coding and circular RNAs.长链非编码RNA和环状RNA对糖尿病肾病中细胞焦亡的调控
Clin Exp Med. 2025 Jun 18;25(1):208. doi: 10.1007/s10238-025-01740-w.
4
The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.细胞因子和分子通路在SARS-CoV-2感染后肺纤维化中的作用：生理病理学（再）综述
Biomedicines. 2024 Mar 13;12(3):639. doi: 10.3390/biomedicines12030639.
5
Gender differences in comorbidities of patients with COVID-19: An Italian local register-based analysis.2019冠状病毒病患者合并症的性别差异：一项基于意大利本地登记处的分析。
Heliyon. 2023 Jul 7;9(7):e18109. doi: 10.1016/j.heliyon.2023.e18109. eCollection 2023 Jul.
6
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors.固有免疫和适应性免疫对 SARS-CoV-2 及相关影响因素。
Front Immunol. 2023 May 9;14:1159326. doi: 10.3389/fimmu.2023.1159326. eCollection 2023.
7
Obesity and Coronavirus Disease 2019.肥胖与2019冠状病毒病
J Transl Int Med. 2022 Sep 24;10(3):207-218. doi: 10.2478/jtim-2022-0020. eCollection 2022 Sep.
8
Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.合并症、相关疾病和 COVID-19 风险评估——系统综述。
Int J Clin Pract. 2022 Oct 31;2022:1571826. doi: 10.1155/2022/1571826. eCollection 2022.
9
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9.新型冠状病毒肺炎后肺纤维化的细胞和分子机制：聚焦半乳糖凝集素-1、-3、-8、-9。
Int J Mol Sci. 2022 Jul 26;23(15):8210. doi: 10.3390/ijms23158210.
10
Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report.肥胖的重症 COVID-19 青少年的恢复期血浆治疗：两例报告。
Ann Med Surg (Lond). 2021 Dec;72:103084. doi: 10.1016/j.amsu.2021.103084. Epub 2021 Nov 18.
本文引用的文献
1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
The potential effects of clinical antidiabetic agents on SARS-CoV-2.临床抗糖尿病药物对 SARS-CoV-2 的潜在影响。
J Diabetes. 2021 Mar;13(3):243-252. doi: 10.1111/1753-0407.13135. Epub 2020 Dec 19.
3
Preliminary Trajectories in Dietary Behaviors during the COVID-19 Pandemic: A Public Health Call to Action to Face Obesity.新冠肺炎疫情期间饮食行为的初步轨迹：应对肥胖的公共卫生行动呼吁。
Int J Environ Res Public Health. 2020 Sep 27;17(19):7073. doi: 10.3390/ijerph17197073.
4
Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.二甲双胍的免疫调节和抗病毒活性及其在治疗 2019 年冠状病毒病和肺损伤中的潜在意义。
Front Immunol. 2020 Aug 18;11:2056. doi: 10.3389/fimmu.2020.02056. eCollection 2020.
5
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?抗糖尿病药物的抗炎特性：COVID-19 时代的“希望之地”？
J Diabetes Complications. 2020 Dec;34(12):107723. doi: 10.1016/j.jdiacomp.2020.107723. Epub 2020 Aug 26.
6
Independent Role of Severe Obesity as a Risk Factor for COVID-19 Hospitalization: A Spanish Population-Based Cohort Study.严重肥胖作为 COVID-19 住院的独立风险因素：一项基于西班牙人群的队列研究。
Obesity (Silver Spring). 2021 Jan;29(1):29-37. doi: 10.1002/oby.23029. Epub 2020 Dec 6.
7
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data.肥胖及其遗传易感性与 COVID-19 重症风险的关联：基于人群队列数据的分析。
Metabolism. 2020 Nov;112:154345. doi: 10.1016/j.metabol.2020.154345. Epub 2020 Aug 22.
8
Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index.新冠病毒是否威胁到我们的睡眠？隔离对睡眠质量和体重指数的影响。
J Transl Med. 2020 Aug 18;18(1):318. doi: 10.1186/s12967-020-02465-y.
9
Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review.肥胖对因 COVID-19 导致的住院和死亡的影响：一项系统评价。
Obes Res Clin Pract. 2020 Sep-Oct;14(5):398-403. doi: 10.1016/j.orcp.2020.07.005. Epub 2020 Jul 23.
10
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
Zotero 插件